Search

Your search keyword '"Goll, Guro Løvik"' showing total 32 results
Start Over Author "Goll, Guro Løvik"
32 results on '"Goll, Guro Løvik"'

1. T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

Author

Wolf, Asia-Sophia, Bjørlykke, Kristin H., Ørbo, Hilde S., Bhandari, Sabin, Solum, Guri, Kjønstad, Ingrid Fadum, Jyssum, Ingrid, Nygaard, Unni C., Kristoffersen, Anja Bråthen, Christensen, Ingrid E., Josefsson, Sarah E., Lund, Katrine Persgård, Chopra, Adity, Osen, Julie Røkke, Chaban, Viktoriia, Tveter, Anne T., Sexton, Joseph, Kvien, Tore K., Jahnsen, Jørgen, Haavardsholm, Espen A., Grødeland, Gunnveig, Vaage, John Torgils, Provan, Sella A., Kared, Hassen, Lund-Johansen, Fridtjof, Munthe, Ludvig A., Syversen, Silje Watterdal, Goll, Guro Løvik, Jørgensen, Kristin Kaasen, and Mjaaland, Siri

Published
2024
Full Text
View/download PDF

2. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials

Author

Brun, Marthe Kirkesæther, Gehin, Johanna E, Bjørlykke, Kristin Hammersbøen, Warren, David John, Klaasen, Rolf A, Sexton, Joseph, Sandanger, Øystein, Kvien, Tore K, Mørk, Cato, Jahnsen, Jørgen, Bolstad, Nils, Jørgensen, Kristin Kaasen, Haavardsholm, Espen A, Goll, Guro Løvik, and Syversen, Silje Watterdal

Published
2024
Full Text
View/download PDF

3. Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients

Author

Kared, Hassen, Alirezaylavasani, Amin, Lund, Katrine Persgård, Chopra, Adity, Tietze, Lisa, de Matos Kasahara, Taissa, Goll, Guro Løvik, Grødeland, Gunnveig, Kaarbø, Mari, Reisæter, Anna Varberg, Hovd, Markus, Heldal, Kristian, Vaage, John Torgils, Lund-Johansen, Fridtjof, Midtvedt, Karsten, Åsberg, Anders, and Munthe, Ludvig A.

Published
2023
Full Text
View/download PDF

5. Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

Author

Bjørlykke, Kristin H, Ørbo, Hilde S, Tveter, Anne T, Jyssum, Ingrid, Sexton, Joseph, Tran, Trung T, Christensen, Ingrid E, Kro, Grete Birkeland, Kvien, Tore K, Jahnsen, Jørgen, Munthe, Ludvig A, Chopra, Adity, Warren, David J, Mjaaland, Siri, Haavardsholm, Espen A, Grødeland, Gunnveig, Provan, Sella A, Vaage, John T, Syversen, Silje Watterdal, Goll, Guro Løvik, and Jørgensen, Kristin Kaasen

Published
2023
Full Text
View/download PDF

6. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Author

Christensen, Ingrid Egeland, Jyssum, Ingrid, Tveter, Anne Therese, Sexton, Joseph, Tran, Trung T., Mjaaland, Siri, Kro, Grete Birkeland, Kvien, Tore K., Warren, David John, Jahnsen, Jørgen, Munthe, Ludvig A., Haavardsholm, Espen A., Vaage, John Torgils, Grødeland, Gunnveig, Lund-Johansen, Fridtjof, Jørgensen, Kristin Kaasen, Syversen, Silje Watterdal, Goll, Guro Løvik, and Provan, Sella Aarrestad

Published
2022
Full Text
View/download PDF

7. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Author

Jyssum, Ingrid, Kared, Hassen, Tran, Trung T, Tveter, Anne T, Provan, Sella A, Sexton, Joseph, Jørgensen, Kristin K, Jahnsen, Jørgen, Kro, Grete B, Warren, David J, Vaage, Eline B, Kvien, Tore K, Nissen-Meyer, Lise-Sofie H, Anderson, Ane Marie, Grødeland, Gunnveig, Haavardsholm, Espen A, Vaage, John Torgils, Mjaaland, Siri, Syversen, Silje Watterdal, Lund-Johansen, Fridtjof, Munthe, Ludvig A, and Goll, Guro Løvik

Published
2022
Full Text
View/download PDF

8. Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

Author

Ørbo, Hilde S, primary, Bjørlykke, Kristin H, additional, Sexton, Joseph, additional, Jyssum, Ingrid, additional, Tveter, Anne T, additional, Christensen, Ingrid E, additional, Mjaaland, Siri, additional, Kvien, Tore K, additional, Grødeland, Gunnveig, additional, Kro, Grete B, additional, Jahnsen, Jørgen, additional, Haavardsholm, Espen A, additional, Munthe, Ludvig A, additional, Provan, Sella A, additional, Vaage, John T, additional, Goll, Guro Løvik, additional, Jørgensen, Kristin Kaasen, additional, and Syversen, Silje Watterdal, additional

Published
2024
Full Text
View/download PDF

9. Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

Author

Kared, Hassen, primary, Jyssum, Ingrid, additional, Alirezaylavasani, Amin, additional, Egner, Ingrid M., additional, The Tran, Trung, additional, Tietze, Lisa, additional, Lund, Katrine Persgård, additional, Tveter, Anne Therese, additional, Provan, Sella A., additional, Ørbo, Hilde, additional, Haavardsholm, Espen A., additional, Vaage, John Torgils, additional, Jørgensen, Kristin, additional, Syversen, Silje Watterdal, additional, Lund-Johansen, Fridtjof, additional, Goll, Guro Løvik, additional, and Munthe, Ludvig A., additional

Published
2024
Full Text
View/download PDF

10. Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases.

Author

Jyssum, Ingrid, Gehin, Johanna E, Sexton, Joseph, Kristianslund, Eirik Klami, Hu, Yi, Warren, David John, Kvien, Tore K, Haavardsholm, Espen A, Syversen, Silje Watterdal, Bolstad, Nils, and Goll, Guro Løvik

Subjects
ANTI-inflammatory agents, FLUORESCENCE polarization immunoassay, RESEARCH funding, RHEUMATOID arthritis, SCIENTIFIC observation, BLOOD collection, LONG-term health care, IMMUNOGLOBULINS, TREATMENT duration, TREATMENT effectiveness, DESCRIPTIVE statistics, DRUG monitoring, ODDS ratio, ADALIMUMAB, COMPARATIVE studies, CONFIDENCE intervals
Abstract

Objectives To explore associations between serum adalimumab level, treatment response and drug survival in order to identify optimal drug levels for therapeutic drug monitoring of adalimumab. Also, to assess the occurrence and risk factors of anti-drug antibody (ADAb) formation. Methods Non-trough adalimumab and ADAb levels were measured by automated fluorescence assays in serum collected after 3 months of adalimumab treatment in patients with RA, PsA or axial SpA (axSpA) included in the observational NOR-DMARD study. Treatment response was evaluated after 3 months and drug survival was evaluated during long-term follow-up. Results In 340 patients (97 RA, 69 PsA, 174 axSpA), the median adalimumab level was 7.3 mg/l (interquartile range 4.0–10.3). A total of 33 (10%) patients developed ADAbs. Findings were comparable across diagnoses. In RA and PsA, adalimumab levels ≥6.0 mg/l were associated with treatment response [odds ratio (OR) 2.2 (95% CI 1.0, 4.4)] and improved drug survival [hazard ratio 0.49 (95% CI 0.27, 0.80)]. In axSpA, a therapeutic level could not be identified, but higher adalimumab levels were associated with response. Factors associated with ADAb formation were previous bDMARD use, no methotrexate comedication and the use of adalimumab originator compared with GP2017. Conclusion Higher adalimumab levels were associated with a better response and improved drug survival for all diagnoses, with a suggested lower threshold of 6.0 mg/l for RA/PsA. This finding, the large variability in drug levels among patients receiving standard adalimumab dose and the high proportion of patients developing ADAbs encourages further investigations into the potential role of therapeutic drug monitoring of adalimumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. T Cell Responses to Repeated SARS-CoV-2 Vaccination and Breakthrough Infections in Patients on TNF Inhibitor Treatment: A Prospective Cohort Study

Author

Wolf, Asia-Sophia, primary, Bjørlykke, Kristin Hammersbøen, additional, Ørbo, Hilde S., additional, Bhandari, Sabin, additional, Solum, Guri, additional, Fadum Kjønstad, Ingrid, additional, Jyssum, Ingrid, additional, Nygaard, Unni C., additional, Kristoffersen, Anja Bråthen, additional, Christensen, Ingrid E., additional, Josefsson, Sarah E., additional, Persgård Lund, Katrine, additional, Chopra, Adity, additional, Tveter, Anne T., additional, Sexton, Joseph, additional, Kvien, Tore K., additional, Jahnsen, Jørgen, additional, Haavardsholm, Espen A., additional, Grødeland, Gunnveig, additional, Vaage, John Torgils, additional, Provan, Sella Aarrestad, additional, Kared, Hassen, additional, Lund-Johansen, Fridtjof, additional, Munthe, Ludvig André, additional, Syversen, Silje Watterdal, additional, Goll, Guro Løvik, additional, Jørgensen, Kristin Kaasen, additional, and Mjaaland, Siri, additional

Published
2024
Full Text
View/download PDF

12. Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Author

Jyssum, Ingrid, primary, Gehin, Johanna E, additional, Sexton, Joseph, additional, Kristianslund, Eirik Klami, additional, Hu, Yi, additional, Warren, David John, additional, Kvien, Tore K, additional, Haavardsholm, Espen A, additional, Syversen, Silje Watterdal, additional, Bolstad, Nils, additional, and Goll, Guro Løvik, additional

Published
2023
Full Text
View/download PDF

13. The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial

Author

Gjefsen, Elisabeth, Bråten, Lars Christian Haugli, Goll, Guro Løvik, Wigemyr, Monica, Bolstad, Nils, Valberg, Morten, Schistad, Elina Iordanova, Marchand, Gunn Hege, Granviken, Fredrik, Selmer, Kaja Kristine, Froholdt, Anne, Haugen, Anne Julsrud, Dagestad, Magnhild Hammersland, Vetti, Nils, Bakland, Gunnstein, Lie, Benedicte Alexandra, Haavardsholm, Espen A., Nilsen, Aksel Thuv, Holmgard, Thor Einar, Kadar, Thomas Istvan, Kvien, Tore, Skouen, Jan Sture, Grøvle, Lars, Brox, Jens Ivar, Espeland, Ansgar, Storheim, Kjersti, and Zwart, John Anker

Published
2020
Full Text
View/download PDF

15. HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases

Author

Brun, Marthe Kirkesæther, primary, Bjørlykke, Kristin Hammersbøen, additional, Viken, Marte K., additional, Stenvik, Grethe‐Elisabeth, additional, Klaasen, Rolf A., additional, Gehin, Johanna E., additional, Warren, David John, additional, Sexton, Joseph, additional, Sandanger, Øystein, additional, Kvien, Tore K., additional, Mørk, Cato, additional, Haavardsholm, Espen A., additional, Jahnsen, Jørgen, additional, Goll, Guro Løvik, additional, Lie, Benedicte A., additional, Bolstad, Nils, additional, Jørgensen, Kristin Kaasen, additional, and Syversen, Silje Watterdal, additional

Published
2023
Full Text
View/download PDF

16. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type

Author

Jørgensen, Kristin Kaasen, primary, Høivik, Marte Lie, additional, Chopra, Adity, additional, Benth, Jūratė Šaltytė, additional, Ricanek, Petr, additional, Moum, Prof Bjørn, additional, Jyssum, Ingrid, additional, Bolstad, Nils, additional, Warren, David John, additional, Vaage, Prof John T., additional, Munthe, Prof Ludvig A., additional, Lundin, Prof Knut E.A, additional, Anisdahl, Karoline, additional, Syversen, Silje Watterdal, additional, Goll, Guro Løvik, additional, Lund-Johansen, Fridtjof, additional, Medhus, Asle W., additional, and Jahnsen, Prof Jørgen, additional

Published
2023
Full Text
View/download PDF

17. Therapeutic drug monitoring in inflammatory bowel disease:implementation, utilization, and barriers in clinical practice in Scandinavia

Author

Bjørlykke, Kristin H., Jahnsen, Jørgen, Brynskov, Jørn, Molander, Pauliina, Eberhardson, Michael, Davidsdottir, Loà G., Sipponen, Taina, Hjortswang, Henrik, Goll, Guro Løvik, Syversen, Silje Watterdal, Langholz, Ebbe, Jørgensen, Kristin K., Steenholdt, Casper, Bjørlykke, Kristin H., Jahnsen, Jørgen, Brynskov, Jørn, Molander, Pauliina, Eberhardson, Michael, Davidsdottir, Loà G., Sipponen, Taina, Hjortswang, Henrik, Goll, Guro Løvik, Syversen, Silje Watterdal, Langholz, Ebbe, Jørgensen, Kristin K., and Steenholdt, Casper

Abstract

Background and aims: Therapeutic drug monitoring (TDM) may optimize biologic and thiopurine therapies in inflammatory bowel disease (IBD). The study aimed to investigate implementation and utilization of TDM in Scandinavia. Methods: A web-based questionnaire on the use of TDM was distributed to Scandinavian gastroenterologists via the national societies. Results: In total, 297 IBD physicians prescribing biologic therapies, equally distributed between community and university hospitals, were included (response rate 42%) (Norway 118 (40%), Denmark 86 (29%), Sweden 50 (17%), Finland 33 (11%), Iceland 10 (3%)). Overall, TDM was applied during biologic therapies by 87%, and for TNF-inhibitors >90%. Among the users, reactive and proactive TDM were utilized by 90% and 63%, respectively. Danish physicians were significantly less inclined to use TDM compared to other Scandinavian countries; (58% vs 98%); OR 0.03 [0.01–0.09], p < 0.001). Reactive TDM was commonly applied at primary (74%) and secondary (99%) treatment failure. Proactive TDM was used by 80% during maintenance therapy and 56% during induction and more commonly utilized in Norway (p < 0.001), and by physicians managing >10 IBD patients/week (p = 0.005). TDM scenarios were interpreted in accord with available evidence but with discrepancies for proactive TDM. The main barriers to TDM were lack of guidelines (51%) and time lag between sampling and results (49%). TDM of thiopurines was routinely used by 87%. Conclusion: TDM of biologic and thiopurine therapies has been broadly implemented into clinical practice in Scandinavia. However, physicians call for TDM guidelines detailing indications and interpretations of test results along with improved test response times.

Published
2023

18. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Author

Syversen, Silje Watterdal, primary, Jyssum, Ingrid, additional, Tveter, Anne Therese, additional, Sexton, Joe, additional, Christensen, Ingrid Egeland, additional, Tran, Trung T, additional, Bjørlykke, Kristin Hammersbøen, additional, Mjaaland, Siri, additional, Warren, David J, additional, Kvien, Tore K, additional, Chopra, Adity, additional, Kro, Grete Birkeland, additional, Jahnsen, Jorgen, additional, Munthe, Ludvig A, additional, Haavardsholm, Espen A, additional, Grødeland, Gunnveig, additional, Vaage, John Torgils, additional, Provan, Sella Aarrestad, additional, Jørgensen, Kristin Kaasen, additional, and Goll, Guro Løvik, additional

Published
2022
Full Text
View/download PDF

19. Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

Author

Bjørlykke, Kristin H., primary, Jahnsen, Jørgen, additional, Brynskov, Jørn, additional, Molander, Pauliina, additional, Eberhardson, Michael, additional, Davidsdottir, Loà G., additional, Sipponen, Taina, additional, Hjortswang, Henrik, additional, Goll, Guro Løvik, additional, Syversen, Silje Watterdal, additional, Langholz, Ebbe, additional, Jørgensen, Kristin K., additional, and Steenholdt, Casper, additional

Published
2022
Full Text
View/download PDF

20. Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

Author

Brun, Marthe Kirkesæther, primary, Goll, Guro Løvik, additional, Jørgensen, Kristin Kaasen, additional, Sexton, Joseph, additional, Gehin, Johanna Elin, additional, Sandanger, Øystein, additional, Olsen, Inge Christoffer, additional, Klaasen, Rolf Anton, additional, Warren, David John, additional, Mørk, Cato, additional, Kvien, Tore K., additional, Jahnsen, Jørgen, additional, Bolstad, Nils, additional, Haavardsholm, Espen A., additional, and Syversen, Silje Watterdal, additional

Published
2022
Full Text
View/download PDF

21. Additional file 1 of The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Author

Christensen, Ingrid Egeland, Jyssum, Ingrid, Tveter, Anne Therese, Sexton, Joseph, Tran, Trung T., Mjaaland, Siri, Kro, Grete Birkeland, Kvien, Tore K., Warren, David John, Jahnsen, Jørgen, Munthe, Ludvig A., Haavardsholm, Espen A., Vaage, John Torgils, Grødeland, Gunnveig, Lund-Johansen, Fridtjof, Jørgensen, Kristin Kaasen, Syversen, Silje Watterdal, Goll, Guro Løvik, and Provan, Sella Aarrestad

Abstract

Additional file 1: Section 1. Inclusion and Exclusion Criteria. Section 2. Supplementary Figures S1-S4. Fig. S1. Flow-chart of analyses population. Fig. S2. Margins plot of the estimated 30 days reduction at different intervals between first and second serum assessment. Fig. S3. Scatter plot of antibody levels and timing of blood sampling. Fig. S4. Levels of anti-RBD antibodies at first and second assessment across diagnoses. Section 3. Supplementary Tables S1-S5. Table S1. Predictors of anti-RBD level at second assessment. Table S2. Median percentage change in anti-RBD level between first and second assessment across diagnoses. Table S3. Serological response at first and second assessment by medication group. Table S4. Linear regression models of estimated percent reduction in anti-RBD level in 30 days in patients with inflammatory joint diseases. Table S5. Linear regression models of estimated percent reduction in anti-RBD level in 30 days in patients with inflammatory bowel diseases.

Published
2022
Full Text
View/download PDF

22. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

Author

Syversen, Silje Watterdal, primary, Jørgensen, Kristin Kaasen, additional, Goll, Guro Løvik, additional, Brun, Marthe Kirkesæther, additional, Sandanger, Øystein, additional, Bjørlykke, Kristin Hammersbøen, additional, Sexton, Joseph, additional, Olsen, Inge Christoffer, additional, Gehin, Johanna Elin, additional, Warren, David John, additional, Klaasen, Rolf Anton, additional, Noraberg, Geir, additional, Bruun, Trude Jannecke, additional, Dotterud, Christian Kvikne, additional, Ljoså, Maud Kristine Aga, additional, Haugen, Anne Julsrud, additional, Njålla, Rune Johan, additional, Zettel, Camilla, additional, Ystrøm, Carl Magnus, additional, Bragnes, Yngvill Hovde, additional, Skorpe, Svanaug, additional, Thune, Turid, additional, Seeberg, Kathrine Aglen, additional, Michelsen, Brigitte, additional, Blomgren, Ingrid Marianne, additional, Strand, Eldri Kveine, additional, Mielnik, Pawel, additional, Torp, Roald, additional, Mørk, Cato, additional, Kvien, Tore K., additional, Jahnsen, Jørgen, additional, Bolstad, Nils, additional, and Haavardsholm, Espen A., additional

Published
2021
Full Text
View/download PDF

23. Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis

Author

Gehin, Johanna Elin, primary, Syversen, Silje Watterdal, additional, Warren, David John, additional, Goll, Guro Løvik, additional, Sexton, Joseph, additional, Bolstad, Nils, additional, and Hammer, Hilde Berner, additional

Published
2021
Full Text
View/download PDF

24. Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia.

Author

Bjørlykke, Kristin H., Jahnsen, Jørgen, Brynskov, Jørn, Molander, Pauliina, Eberhardson, Michael, Davidsdottir, Loà G., Sipponen, Taina, Hjortswang, Henrik, Goll, Guro Løvik, Syversen, Silje Watterdal, Langholz, Ebbe, Jørgensen, Kristin K., and Steenholdt, Casper

Subjects
DRUG monitoring, INFLAMMATORY bowel diseases, BIOTHERAPY, PHYSICIANS, COMMUNITIES
Abstract

Therapeutic drug monitoring (TDM) may optimize biologic and thiopurine therapies in inflammatory bowel disease (IBD). The study aimed to investigate implementation and utilization of TDM in Scandinavia. A web-based questionnaire on the use of TDM was distributed to Scandinavian gastroenterologists via the national societies. In total, 297 IBD physicians prescribing biologic therapies, equally distributed between community and university hospitals, were included (response rate 42%) (Norway 118 (40%), Denmark 86 (29%), Sweden 50 (17%), Finland 33 (11%), Iceland 10 (3%)). Overall, TDM was applied during biologic therapies by 87%, and for TNF-inhibitors >90%. Among the users, reactive and proactive TDM were utilized by 90% and 63%, respectively. Danish physicians were significantly less inclined to use TDM compared to other Scandinavian countries; (58% vs 98%); OR 0.03 [0.01–0.09], p < 0.001). Reactive TDM was commonly applied at primary (74%) and secondary (99%) treatment failure. Proactive TDM was used by 80% during maintenance therapy and 56% during induction and more commonly utilized in Norway (p < 0.001), and by physicians managing >10 IBD patients/week (p = 0.005). TDM scenarios were interpreted in accord with available evidence but with discrepancies for proactive TDM. The main barriers to TDM were lack of guidelines (51%) and time lag between sampling and results (49%). TDM of thiopurines was routinely used by 87%. TDM of biologic and thiopurine therapies has been broadly implemented into clinical practice in Scandinavia. However, physicians call for TDM guidelines detailing indications and interpretations of test results along with improved test response times. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia

Author

Holm, Sverre, primary, Kared, Hassen, additional, Michelsen, Annika E, additional, Kong, Xiang Yi, additional, Dahl, Tuva B, additional, Schultz, Nina H, additional, Nyman, Tuula A, additional, Fladeby, Cathrine, additional, Seljeflot, Ingebjørg, additional, Ueland, Thor, additional, Stensland, Maria, additional, Mjaaland, Siri, additional, Goll, Guro Løvik, additional, Nissen-Meyer, Lise Sofie, additional, Aukrust, Pål, additional, Skagen, Karolina, additional, Gregersen, Ida, additional, Skjelland, Mona, additional, Holme, Pål A, additional, Munthe, Ludvig A, additional, and Halvorsen, Bente, additional

Published
2021
Full Text
View/download PDF

26. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases

Author

Syversen, Silje Watterdal, primary, Goll, Guro Løvik, additional, Jørgensen, Kristin Kaasen, additional, Sandanger, Øystein, additional, Sexton, Joseph, additional, Olsen, Inge Christoffer, additional, Gehin, Johanna Elin, additional, Warren, David John, additional, Brun, Marthe Kirkesæther, additional, Klaasen, Rolf Anton, additional, Karlsen, Lars Normann, additional, Noraberg, Geir, additional, Zettel, Camilla, additional, Ljoså, Maud Kristine Aga, additional, Haugen, Anne Julsrud, additional, Njålla, Rune Johan, additional, Bruun, Trude Jannecke, additional, Seeberg, Kathrine Aglen, additional, Michelsen, Brigitte, additional, Strand, Eldri Kveine, additional, Skorpe, Svanaug, additional, Blomgren, Ingrid Marianne, additional, Bragnes, Yngvill Hovde, additional, Dotterud, Christian Kvikne, additional, Thune, Turid, additional, Ystrøm, Carl Magnus, additional, Torp, Roald, additional, Mielnik, Pawel, additional, Mørk, Cato, additional, Kvien, Tore K., additional, Jahnsen, Jørgen, additional, Bolstad, Nils, additional, and Haavardsholm, Espen A., additional

Published
2021
Full Text
View/download PDF

27. Kristin Holstad

Author

Ødegård, Sigrid, primary, Bergsmark, Kjetil, primary, Goll, Guro Løvik, primary, and Uhlig, Till, primary

Published
2021
Full Text
View/download PDF

28. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

Author

Syversen, Silje Watterdal, primary, Goll, Guro Løvik, additional, Jørgensen, Kristin Kaasen, additional, Olsen, Inge Christoffer, additional, Sandanger, Øystein, additional, Gehin, Johanna Elin, additional, Warren, David John, additional, Sexton, Joseph, additional, Mørk, Cato, additional, Jahnsen, Jørgen, additional, Kvien, Tore Kristian, additional, Bolstad, Nils, additional, and Haavardsholm, Espen A., additional

Published
2019
Full Text
View/download PDF

31. Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis:Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry

Author

Glintborg, Bente, Kringelbach, Tina Marie, Høgdall, Estrid Vilma Solyom, Sørensen, Inge Juul, Jensen, Dorte Vendelbo, Loft, Anne Gitte, Hendricks, Oliver, Hansen, Inger Marie Jensen, Linauskas, Asta, Kristensen, Salome, Lindegaard, Hanne, Nordin, Henrik, Bolstad, Nils, Warren, David, Gehin, Johanna, Goll, Guro Løvik, Grøn, Kathrine Lederballe, Eng, Grith, Enevold, Christian, Nielsen, Claus Henrik, Johansen, Julia Sidenius, Hetland, Merete Lund, Glintborg, Bente, Kringelbach, Tina Marie, Høgdall, Estrid Vilma Solyom, Sørensen, Inge Juul, Jensen, Dorte Vendelbo, Loft, Anne Gitte, Hendricks, Oliver, Hansen, Inger Marie Jensen, Linauskas, Asta, Kristensen, Salome, Lindegaard, Hanne, Nordin, Henrik, Bolstad, Nils, Warren, David, Gehin, Johanna, Goll, Guro Løvik, Grøn, Kathrine Lederballe, Eng, Grith, Enevold, Christian, Nielsen, Claus Henrik, Johansen, Julia Sidenius, and Hetland, Merete Lund

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results